Ekso Bionics to Participate at the H.C. Wainwright BioConnect Virtual Conference

RICHMOND, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that management will participate in a fireside chat at the H.C. Wainwright BioConnect Virtual Conference taking place January 10-13, 2022.

The fireside chat will be available to view on-demand as of 4:00 AM PT / 7:00 AM ET, Monday, January 10, 2022 throughout the entirety of the conference and on the investor section of the Company’s website at www.eksobionics.com.

About Ekso Bionics® 
Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance, and mobility across medical and industrial applications. Founded in 2005, the Company continues to build upon its industry-leading expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. Ekso Bionics is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol “EKSO.” For more information, visit: www.eksobionics.com or follow @EksoBionics on Twitter.

Investor Contact:
David Carey
212-867-1768
investors@eksobionics.com


Primary Logo

Source: Ekso Bionics Holdings, Inc.